含喹喔啉杨梅素衍生物的合成及生物活性

利用活性拼接原理, 将喹喔啉引入到杨梅素结构中, 合成了一系列含喹喔啉基团的杨梅素新型衍生物. 采用浊度法测试了目标化合物的体外抑菌活性, 结果表明, 目标化合物对柑橘溃疡病菌(X. Citri)和水稻白叶枯病菌(X. Oryzae)均表现出较好的抑制活性. 目标化合物对柑橘溃疡病菌的抑制活性(EC₅₀)均优于对照药叶枯唑和噻菌铜(EC₅₀分别为54.85和61.13 μg/mL), 其中化合物4o抑制活性(EC₅₀=11.17 μg/mL)最优; 目标化合物对水稻白叶枯病菌的抑制活性EC₅₀均优于对照药叶枯唑和噻菌铜(EC₅₀分别为148.20和175.47 μg/mL), 其中化合物4f抑制活性(EC₅₀=34.49 μg/mL)最优. 采用半叶枯斑法测试了目标化合物的抗烟草花叶病毒(TMV)活性, 结果表明, 所有目标化合物在浓度为500 mg/L时均有一定的抑制作用.

Synthesis and Biological Activities of Myricetin Derivatives Containing Quinoxaline†

According to the active substructure combination theory, a series of novel myricetin derivatives containing quinoxaline moieties was synthesized by introducing the quinoxaline blocks into the structures of myricetins. The antibacterial activities of the target compounds were evaluated via turbidimeter test in vitro. The preliminary bioassay results indicated that all of the title compounds exhibited certain antibacterial activities in vitro against Xanthomonas axonopodis pv. Citri(X. citri) and Xanthomonas oryzae pv. Oryzae(X. oryzae). The compounds were also tested to evaluate the half maximal effective concentration(EC₅₀) of phytopathogenic bacteria. The results showed that all the X. citri EC₅₀ of the target compounds were superior to those of the control drugs of bismerthiazol and thiodiazole copper(54.85 and 61.13 μg/mL, respectively). Compound 4o(EC₅₀=11.17 μg/mL) exhibited the best activity. All of the X. oryzae EC₅₀ of the target compounds were superior to the control drugs of bismerthiazol and thiodiazole copper(148.20 and 175.47 μg/mL, respectively). Compound 4f(EC₅₀=34.49 μg/mL) exhibited the best activity. The in vivo efficacies against tobacco mosaic virus(TMV) of the target compounds were tested through half-leaf method. The results of bioassay showed that the target compounds exhibited certain anti-TMV activities at the concentration of 500 mg/L.